A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

Completed · Phase 1

Conditions studied: Hairy Cell Leukemia

In brief

A dose-escalation study to identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), defined as the highest dose that can safely be given to a participant and establish the safest dose based on the highest tolerated dose for clinical testing.

Key facts

Study ID

NCT00586924

Run by

MedImmune LLC

People needed

49

Starts

2007-05-10

Expected to finish

2015-05-06

Last updated by the study team

2019-04-02

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Stanford, California, United States
• Research Site — Chicago, Illinois, United States
• Research Site — Bethesda, Maryland, United States
• Research Site — Lodz, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.